AYJK(002172)

Search documents
澳洋健康(002172) - 2015 Q4 - 年度财报
2016-03-09 16:00
Financial Performance - The company's operating revenue for 2015 was CNY 3,808,778,593.35, a decrease of 18.55% compared to CNY 4,676,187,852.26 in 2014[18] - The net profit attributable to shareholders in 2015 was CNY 135,862,289.26, representing a significant increase of 288.90% from a loss of CNY 71,923,164.82 in 2014[18] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 97,411,908.54, up 215.49% from a loss of CNY 84,345,929.94 in 2014[18] - Basic earnings per share for 2015 were CNY 0.1955, compared to a loss of CNY 0.110 in 2014, marking an increase of 263.64%[18] - The total revenue for the year 2015 was CNY 3,808,778,593.35, a decrease of 18.55% compared to CNY 4,676,187,852.26 in 2014[35] - The net profit attributable to the parent company was CNY 135,862,289.26, an increase of 288.50% from the previous year[35] - The company's total revenue for the chemical fiber segment reached ¥2,294,215,869.02, a decrease of 21.73% compared to the previous year, with a gross margin of 13.75%[42] - The pharmaceutical logistics segment generated revenue of ¥835,113,227.00, down 25.92% year-over-year, with a gross margin of 10.24%[42] - Medical services revenue increased by 9.99% to ¥679,449,497.33, with a gross margin of 18.21%[42] Cash Flow and Assets - The company's cash flow from operating activities was CNY 334,683,988.37, down 43.20% from CNY 589,230,620.42 in 2014[18] - The total assets at the end of 2015 were CNY 3,675,759,617.95, a slight increase of 1.66% from CNY 3,615,841,140.88 at the end of 2014[19] - The net assets attributable to shareholders increased by 52.59% to CNY 1,018,986,643.02 at the end of 2015, up from CNY 667,815,411.20 at the end of 2014[19] - The net cash flow from operating activities decreased by 43.20% compared to the previous year, primarily due to a decline in cash paid for goods[54] - The net cash flow from investment activities increased by 39.06% year-on-year, mainly due to reduced cash outflows for fixed asset construction[54] - The net cash flow from financing activities improved by 87.77% compared to the previous year, primarily due to a decrease in debt repayment during 2015[55] - The net increase in cash and cash equivalents was 125,517,649.29 yuan, a significant increase of 389.37% compared to the previous year[54] - As of the end of 2015, cash and cash equivalents amounted to 461,090,805.6 yuan, representing 12.54% of total assets, up from 10.94% in 2014[56] Business Strategy and Expansion - The company successfully transitioned to the health industry by acquiring 100% equity of Aoyang Health Investment in 2015, forming a dual business structure of chemical fibers and health[16] - The company plans to expand its rehabilitation medical services and enhance its brand presence in the Jiangsu region[35] - The company aims to increase the production of differentiated viscose fibers while reducing the output of regular viscose fibers[32] - The company has established a modern pharmaceutical distribution network covering East China, positioning itself as one of the largest private logistics enterprises in the region[31] - The company plans to enhance investment in the health industry, focusing on building a regional information platform and expanding medical services[69] - The fiber business strategy aims to optimize product structure and stabilize profitability, with a focus on high-tech products and external cooperation[70] Shareholder and Governance - The company did not distribute cash dividends or bonus shares in 2015[5] - The company has not proposed any cash dividends for the reporting period, despite having a positive profit available for distribution[76] - The company is committed to fulfilling its promises related to asset restructuring and has been performing normally in this regard[77] - The company has a lock-up period for institutional shares, with a release date of July 16, 2015, for certain shareholders[121] - The total number of shareholders at the end of the reporting period was 45,878, an increase from 45,760 at the end of the previous month[125] - The largest shareholder, Aoyang Group Co., Ltd., holds 51.83% of the shares, amounting to 240,082,979 shares, with a pledge status[126] - The company has established a governance structure in compliance with relevant laws and regulations, ensuring independent operation from its controlling shareholder[169] - The audit committee held 6 meetings during the reporting period, addressing internal audit activities and recommending a change in accounting firms to meet the company's development needs[174] Employee and Management - The total number of employees at Jiangsu Aoyang Technology Co., Ltd. as of December 31, 2015, is 4,671[154] - The company has 657 nursing staff, representing 14.07% of the total employee count[155] - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 2,361,500 CNY (approximately 236.15 million CNY)[152] - The average salary for executives is CNY 138,900 per person, while the average salary for all employees is CNY 69,700 per person[157] - The company emphasizes the importance of corporate governance, with a structured approach to board and management roles[142] - The leadership team includes professionals with advanced degrees and certifications, enhancing the company's strategic capabilities[139][146] Risks and Challenges - The company faces risks related to raw material price fluctuations and domestic and international demand volatility[4] - The company is classified as a heavy polluter according to national environmental protection standards[115] - The company did not publish a social responsibility report for the reporting period[115] Audit and Compliance - The audit opinion issued by the accounting firm was a standard unqualified opinion, confirming that the financial statements fairly represent the company's financial position[182] - The company maintained effective internal controls related to financial reporting as of December 31, 2015, according to the internal control verification report[180] - The company reported zero significant defects in internal controls for both financial and non-financial reports, indicating effective internal control systems[179]
澳洋健康(002172) - 2015 Q3 - 季度财报
2015-10-29 16:00
江苏澳洋科技股份有限公司 2015 年第三季度报告正文 证券代码:002172 证券简称:澳洋科技 公告编号:2015-68 江苏澳洋科技股份有限公司 2015 年第三季度报告正文 2015 年 10 月 30 日 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚 假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈学如、主管会计工作负责人马科文及会计机构负责人(会计主管人员)马科文声明:保证 季度报告中财务报表的真实、准确、完整。 2 江苏澳洋科技股份有限公司 2015 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 1 江苏澳洋科技股份有限公司 2015 年第三季度报告正文 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产(元) | 3,629,520,725.35 | ...
澳洋健康(002172) - 2015 Q2 - 季度财报
2015-08-24 16:00
Financial Performance - The company's operating revenue for the first half of 2015 was CNY 1,144,934,230.60, a decrease of 22.04% compared to CNY 1,468,556,806.45 in the same period last year[21]. - Net profit attributable to shareholders was CNY 23,929,165.22, a significant increase of 152.56% from a loss of CNY 45,531,128.64 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 7,989,994.70, up 116.28% from a loss of CNY 49,092,971.05 in the same period last year[21]. - The basic earnings per share improved to CNY 0.04 from a loss of CNY 0.08 in the same period last year, reflecting a 150% increase[21]. - The weighted average return on net assets was 4.52%, an increase of 12.03% compared to -7.51% in the previous year[21]. - The company achieved operating revenue of CNY 1,144,934,230.60, a decrease of 22.04% compared to the same period last year[30]. - Net profit attributable to shareholders increased by 152.56% to CNY 23,929,165.22[30]. - Operating costs decreased by 25.14% to CNY 1,021,068,581.16, while sales expenses dropped by 42.96% to CNY 38,172,199.83[31]. - The company reported a total comprehensive income for the first half of 2015 of CNY 15,499,045.68, compared to a loss of CNY 58,451,829.79 in the same period last year[118]. - The company expects a net profit of CNY 65 million to CNY 85 million for the first three quarters of 2015, a turnaround from a net loss of CNY 45.53 million in the same period last year[53]. Asset and Equity Changes - The company's total assets increased by 11.99% to CNY 2,678,689,361.25 compared to CNY 2,391,844,498.58 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 44.21% to CNY 746,408,743.81 from CNY 517,573,620.56 at the end of the previous year[21]. - The total assets of Jiangsu Aoyang Technology Co., Ltd. as of June 30, 2015, amounted to RMB 2,678,689,361.24, an increase from RMB 2,391,844,498.58 at the beginning of the period[107]. - The total equity attributable to the parent company at the end of the period was ¥574,733,592.00, up from ¥559,348,977.00, reflecting an increase of about 2.5%[132]. - The total liabilities increased to CNY 1,779,137,080.18 from CNY 1,712,706,004.13, an increase of approximately 3.9%[110]. Cash Flow and Financing Activities - The company reported a significant increase in cash flow from financing activities, rising by 271.32% to CNY 176,509,165.93[31]. - The net increase in cash and cash equivalents was CNY 239,068,253.69, representing a 642.43% increase[32]. - The company raised CNY 205,249,994.75 from new investments during the first half of 2015[126]. - The company's total cash inflow from financing activities was CNY 973,435,244.17, compared to CNY 910,133,000.00 in the previous year[126]. - Cash inflow from financing activities totaled ¥254,463,497.93, a substantial increase from ¥48,000,000.00, reflecting a growth of over 429%[129]. Strategic Acquisitions and Investments - The company completed the acquisition of Aoyang Health Investment, marking its successful entry into the healthcare industry[28]. - The company plans to combine internal development and external expansion to strengthen its healthcare business[34]. - The total amount of raised funds was CNY 204,905,958.03 after deducting related expenses, aimed at acquiring 100% equity of Aoyang Health Investment[43]. - The company plans to increase its investment in Aoyang Health Investment by CNY 210 million to supplement its working capital[46]. - The company completed the acquisition of Jiangsu Aoyang Health Industry Investment Co., Ltd. for a transaction price of 65 million yuan, positively impacting the company's performance in the third quarter[63]. Operational Developments - The company aims to accelerate environmental investments and inspections at its Xinjiang production base to resume production as soon as possible[28]. - The company plans to adjust the product structure at its Funiing production base to increase the proportion of differentiated products and enhance profitability[28]. - The company has a production capacity of 300,000 tons for viscose staple fiber, enhancing its competitive edge in the industry[34]. Corporate Governance and Compliance - The company’s governance practices comply with the requirements of the Company Law and relevant regulations[60]. - The financial report for the first half of 2015 was not audited[105]. - The company did not undergo any penalties or rectifications during the reporting period[87]. - The company has committed to timely fulfill its promises to minority shareholders[91]. Related Party Transactions - The total amount of related party transactions was 1,081.79 million yuan, with a significant portion related to procurement and labor services[70]. - The company’s related party transactions were conducted at market prices, ensuring compliance with regulatory requirements[70]. - There were no significant related party transactions during the reporting period, indicating stable operational integrity[73][74][75]. Financial Reporting and Accounting Policies - The company operates under the Chinese accounting standards, ensuring that its financial statements are accurate and complete[149]. - The company prepares consolidated financial statements based on its own and its subsidiaries' financial reports, determining the scope of consolidation based on control[154]. - The company recognizes the net profit attributable to minority shareholders in the consolidated profit statement under "minority shareholders' profit and loss"[156]. - The company recognizes impairment losses for financial assets measured at amortized cost based on the difference between the book value and the present value of expected future cash flows discounted at the original effective interest rate[168].
澳洋健康(002172) - 2015 Q1 - 季度财报
2015-04-26 16:00
Financial Performance - The company's operating revenue for Q1 2015 was ¥563,256,853.34, a decrease of 9.90% compared to ¥625,142,746.90 in the same period last year[8] - The net profit attributable to shareholders of the listed company was -¥6,785,995.52, an improvement of 78.99% from -¥32,305,993.73 year-on-year[8] - The net cash flow from operating activities increased by 152.80% to ¥34,583,864.93, compared to -¥65,501,730.23 in the previous year[8] - The weighted average return on net assets improved to -1.32%, up by 3.88% from -5.20% in the same period last year[8] - The estimated net profit for the first half of 2015 is projected to be between -15 million to -5 million RMB, compared to a net loss of 45.53 million RMB in the same period of 2014[20] Asset Management - Total assets at the end of the reporting period were ¥2,485,179,106.20, reflecting a growth of 3.90% from ¥2,391,844,498.58 at the end of the previous year[8] - Other current assets increased by 38.61% due to an increase in the value-added tax retained at the end of the reporting period[15] - Prepayments grew by 110.01% as a result of increased customer prepayments for viscose[15] - The company reported a 120.11% decrease in asset impairment losses compared to the previous year, indicating better asset management[15] Cash Flow - The net cash flow from investment activities increased by 82.59%, attributed to lower cash payments for fixed asset purchases compared to the previous year[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,388, with the top ten shareholders holding a combined 42.92% of shares[11] - The company plans to issue shares to acquire 100% equity of Aoyang Jiantou from its controlling shareholder Aoyang Group and other nine individual shareholders[17] Market Conditions - The market price of viscose staple fiber is relatively stable compared to the same period last year, but remains at a low level, with an improvement in gross profit margin compared to the previous year[20]
澳洋健康(002172) - 2014 Q4 - 年度财报
2015-02-16 16:00
Financial Performance - The company's operating revenue for 2014 was ¥2,931,164,388.35, a decrease of 10.57% compared to ¥3,277,439,678.62 in 2013[21] - The net profit attributable to shareholders was -¥104,267,461.75, representing a decline of 598.59% from a profit of ¥20,912,531.41 in the previous year[21] - The basic earnings per share for 2014 was -¥0.19, down 575.00% from ¥0.04 in 2013[21] - The weighted average return on equity was -18.25%, a decline of 21.70% compared to 3.45% in the previous year[21] - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 494.92 million, up 107.32% from the previous year[41] - The company reported a net loss of CNY 537,248,171.54, compared to a loss of CNY 432,980,709.79 in the previous period[177] - The company's operating revenue for the current period was CNY 2,245,121,868.90, a decrease of 11.95% compared to CNY 2,549,515,997.08 in the previous period[186] - The net profit for the current period was a loss of CNY 131,692,493.58, compared to a net profit of CNY 22,552,488.19 in the previous period[185] Assets and Liabilities - The total assets at the end of 2014 were ¥2,391,844,498.58, a decrease of 16.26% from ¥2,856,120,624.39 at the end of 2013[21] - The net assets attributable to shareholders decreased by 18.83% to ¥517,573,620.56 from ¥637,616,164.89 in 2013[21] - The total assets at the end of the period were CNY 2,391,844,498.58, compared to CNY 2,856,120,624.39 at the beginning of the period, representing a decrease of 16.36%[177] - Total liabilities decreased to CNY 1,712,706,004.13 from CNY 2,021,236,636.00, a reduction of 15.26%[177] - Cash and cash equivalents decreased to CNY 37,132,929.30 from CNY 51,612,846.95, a decline of 28.14%[178] Revenue and Sales - The company achieved total operating revenue of CNY 2,931.16 million in 2014, a decrease of 10.57% compared to the previous year, primarily due to the decline in viscose staple fiber market prices[30] - The production volume of viscose staple fiber was 273,389.6 tons, a decrease of 4.32% from 2013, while sales volume increased by 1.50% to 282,852.56 tons[32] - The average price of viscose staple fiber fell from CNY 12,500 per ton at the beginning of the year to a historical low of CNY 11,400 per ton in March 2014, with a year-end price again touching CNY 11,400[29] - The company reported a decrease in sales revenue from 1,231,348,372.55 CNY to 1,190,985,972.85 CNY, reflecting a decline of approximately 3.5% year-over-year[191] Cash Flow - The net cash flow from operating activities increased by 107.32% to ¥494,924,498.76, up from ¥238,730,309.40 in 2013[21] - The net cash flow from investing activities decreased by 89.14%, mainly due to higher cash payments for fixed asset purchases compared to the previous year[42] - The net cash flow from financing activities decreased by 117.02%, primarily due to cash payments for loan repayments and a reduction in loan balances[42] - The cash inflow from operating activities totaled CNY 1,202,831,984.80, down from CNY 1,304,968,398.37 in the previous period[189] Dividends and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company did not distribute cash dividends in 2014, with a net profit attributable to shareholders of CNY -104,267,461.75[60] - The company completed the grant of restricted stock under the incentive plan, totaling 3,168,000 shares for 44 recipients who had not met the unlocking conditions[74] Risks and Challenges - The company faces risks related to product and raw material price fluctuations, as well as domestic and international demand volatility[13] - The company reported an investment loss of CNY 120,000,000.00 in the current period, with no investment income reported in the previous period[186] Governance and Management - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring the protection of minority shareholders' rights[140] - The independent directors attended 10 board meetings, with an average of 8 in-person attendances[150] - The company has a diverse leadership team with extensive experience across various sectors, including finance, management, and engineering[116][118][120] Employee and Human Resources - As of December 31, 2014, Jiangsu Aoyang Technology Co., Ltd. had a total of 2,873 employees, with 76.50% being production personnel[133] - The employee composition indicates a strong focus on production, with 76.50% of the workforce engaged in production roles[133] - The total compensation for key management personnel amounted to 2,950,000, with the finance director receiving 800,000[131] Related Party Transactions - The company reported a total of 2,422.88 million yuan in related party transactions, with the largest transaction being the sale of electrical products amounting to 2,212.51 million yuan[76] - The company confirmed that all related party transactions were conducted at market prices and did not affect its independence[77]
澳洋健康(002172) - 2014 Q3 - 季度财报
2014-10-29 16:00
江苏澳洋科技股份有限公司 2014 年第三季度报告正文 证券代码:002172 证券简称:澳洋科技 公告编号:2014-49 江苏澳洋科技股份有限公司 2014 年第三季度报告正文 2014 年 10 月 30 日 1 江苏澳洋科技股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚 假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈学如、主管会计工作负责人马科文及会计机构负责人(会计主管人员)马科文声明:保证 季度报告中财务报表的真实、准确、完整。 2 江苏澳洋科技股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产(元) | 2,644,029,893.17 | ...
澳洋健康(002172) - 2014 Q2 - 季度财报
2014-08-25 16:00
Financial Performance - The company reported a revenue of ¥1,468,556,806.45, a decrease of 9.67% compared to the same period last year[18]. - The net profit attributable to shareholders was a loss of ¥45,531,128.64, representing a decline of 277.20% year-on-year[18]. - The net cash flow from operating activities was ¥141,317,047.51, down 42.80% from the previous year[18]. - The company's operating revenue for the reporting period was ¥1,468,556,806.45, a decrease of 9.67% compared to the same period last year[25]. - Operating costs amounted to ¥1,364,027,441.56, reflecting a reduction of 4.42% year-on-year[25]. - The company anticipates a net loss of between ¥60 million and ¥40 million for the first nine months of 2014, compared to a profit of ¥25.69 million in the same period last year[34]. - The company reported a gross margin of 6.79% in the chemical fiber industry, down from the previous year[28]. - The company reported a net loss of ¥58,451,829.79 compared to a net profit of ¥26,831,764.31 in the previous period, indicating a significant downturn[92]. - The basic and diluted earnings per share were both -¥0.08, down from ¥0.05 in the prior period[92]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,938,669,728.93, an increase of 2.89% compared to the end of the previous year[18]. - The total liabilities increased to CNY 2,170,442,690.33 from CNY 2,021,236,636.00, indicating a rise in financial obligations[86]. - The company's equity attributable to shareholders decreased to CNY 583,879,916.25 from CNY 637,616,164.89, reflecting a decline in retained earnings[86]. - The total current liabilities rose to CNY 2,129,610,287.23 from CNY 1,976,921,712.49, indicating increased short-term financial pressures[86]. - The total accounts receivable at the end of the period amounted to ¥75,369,114, with a bad debt provision of ¥5,396,437.8, representing 7.16% of the total[200]. Cash Flow - The net cash flow from investing activities improved by 76.01%, with a net outflow of ¥6,088,494.79 compared to a larger outflow in the previous year[25]. - The net cash flow from financing activities decreased by 46.12%, resulting in a net outflow of ¥103,028,452.87[25]. - Cash flow from operating activities generated a net cash inflow of ¥141,317,047.51, a decrease from ¥247,078,833.97 in the previous period[98]. - The total cash outflow for financing activities was 1,013,161,452.87, indicating a high level of financial obligations[99]. - The company’s cash inflow from operating activities was significantly lower than the previous period, indicating potential challenges in revenue generation[100]. Business Operations - The company’s main business, viscose staple fiber, accounted for 99.18% of total revenue[24]. - The viscose staple fiber market experienced a slight price decline, with prices stabilizing and slightly recovering in the second quarter[23]. - The company is focusing on cost reduction and efficiency improvement to enhance its competitive advantage in a challenging market environment[23]. - The company plans to optimize inventory management and adjust production strategies based on market trends[23]. - The company operates in the viscose staple fiber industry, focusing on the production and sales of viscose fibers, biodegradable fibers, and functional fibers[122]. Shareholder Information - The company will not distribute cash dividends or issue bonus shares for this period[4]. - The total number of ordinary shareholders at the end of the reporting period was 38,818[75]. - The largest shareholder, Aoyang Group Co., Ltd., holds 42.67% of the shares, with a total of 240,082,979 shares[75]. - The company has committed to ensuring that no more than 25% of its total shares will be transferred during the tenure of its major shareholder[65]. - The company has maintained compliance with its commitments regarding share transfers and has not faced any penalties or rectifications during the reporting period[68][69]. Research and Development - The company has established a research and development center for differentiated viscose products, which has led to the development of multiple patented technologies[29]. - The company plans to continue its market expansion efforts, focusing on enhancing its product offerings and technological advancements[113]. - The company has outlined strategies for potential mergers and acquisitions to further strengthen its market presence and operational capabilities[186]. Compliance and Governance - No significant changes in profit structure or major litigation issues were reported during the period[26][40]. - The company did not engage in any major transactions or events that require additional explanation during the reporting period[69]. - The financial report for the half-year period has not been audited[68]. - The company did not undergo any changes in its board of directors or senior management during the reporting period[81]. Accounting Policies - The financial statements are prepared based on the assumption of going concern and comply with the accounting standards issued by the Ministry of Finance[123][124]. - The company recognizes financial assets transferred to other parties based on the transfer of risks and rewards associated with those assets[137]. - The company conducts impairment testing on financial assets, recognizing impairment losses when the present value of expected future cash flows is less than the carrying amount[140]. - The company assesses deferred tax assets based on the likelihood of future taxable income to utilize temporary differences[178].
澳洋健康(002172) - 2014 Q1 - 季度财报
2014-04-28 16:00
江苏澳洋科技股份有限公司 2014 年第一季度报告正文 证券代码:002172 证券简称:澳洋科技 公告编号:2014-28 江苏澳洋科技股份有限公司 2014 年第一季度报告正文 2014 年 04 月 29 日 第二节 主要财务数据及股东变化 1 江苏澳洋科技股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈学如、主管会计工作负责人及会计机构负责人(会计主管人员) 马科文声明:保证季度报告中财务报表的真实、准确、完整。 2 江苏澳洋科技股份有限公司 2014 年第一季度报告正文 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | (%) | | 营业收入(元) | 625,142,746.90 ...
澳洋健康(002172) - 2013 Q4 - 年度财报
2014-03-21 16:00
Financial Performance - The company's operating revenue for 2013 was ¥3,277,439,678.62, a decrease of 7.74% compared to ¥3,552,361,540.76 in 2012[21] - The net profit attributable to shareholders for 2013 was ¥20,912,531.41, down 41.34% from ¥35,652,820.63 in the previous year[21] - The net cash flow from operating activities was ¥238,730,309.40, reflecting a decline of 56.14% from ¥544,264,366.22 in 2012[21] - The basic earnings per share for 2013 was ¥0.04, a decrease of 33.33% compared to ¥0.06 in 2012[21] - Total assets at the end of 2013 amounted to ¥2,856,120,624.39, a decrease of 3.13% from ¥2,948,288,007.40 at the end of 2012[21] - The net profit for Q1 2014 is expected to be negative, ranging from -25 million to -35 million RMB, compared to a net profit of 16.63 million RMB in Q1 2013[59] - The decline in performance is primarily due to the continuous drop in the price of viscose staple fiber, poor sales, and an increase in inventory requiring impairment provisions[59] Cash Flow and Investments - The company’s cash flow from operating activities decreased by 71.19% to CNY 1,304,968,398.37[35] - Cash and cash equivalents decreased by 129.99% compared to the previous year[36] - The net cash flow from investment activities was -¥96.18 million, worsening from -¥28.07 million in the previous year[171] - Cash inflow from financing activities increased to ¥1.69 billion, up 19.8% from ¥1.41 billion in the previous year[168] - The company paid ¥1.73 billion in debt repayments, slightly lower than ¥1.74 billion in the previous year[168] Assets and Liabilities - Total current assets amounted to CNY 1,124,699,018.88, an increase from CNY 1,086,137,990.74 in the previous year, reflecting a growth of approximately 3.5%[151] - Total non-current assets decreased to CNY 1,731,421,605.51 from CNY 1,862,150,016.66, indicating a decline of about 7%[152] - Total liabilities were reported at CNY 2,021,236,636.00, down from CNY 2,162,798,862.30, representing a reduction of approximately 6.5%[153] - Shareholders' equity increased to CNY 834,883,988.39 from CNY 785,489,145.10, showing an increase of about 6.3%[153] Production and Sales - The company increased production and sales of differentiated products, such as flame-retardant fibers, in response to market demand[26] - The company’s production volume increased by 9.70% to 285,738.68 tons[29] - The company's annual production capacity for viscose staple fiber is 300,000 tons, with a focus on differentiated viscose development to enhance product value[44] Research and Development - Research and development expenses amounted to CNY 4,283,207.13, representing 0.13% of operating revenue[33] - The company has established a research and development center with multiple patented technologies for differentiated products[44] - The company has invested 50 million RMB in R&D for new technologies aimed at enhancing production efficiency[105] Market Strategy and Competition - The viscose staple fiber industry is experiencing intense competition, leading to a focus on differentiated products to maintain profitability[52] - The company plans to increase the production and sales ratio of differentiated products in 2014, aiming to improve overall competitiveness[51] - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next three years[105] Governance and Compliance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, including the formulation of internal control rules[116] - The board of directors consists of specialized committees, enhancing decision-making processes and governance structure[119] - The company maintains compliance with the Company Law and relevant regulations from the China Securities Regulatory Commission[126] Shareholder Information - The total number of shareholders increased from 41,790 to 43,268 during the reporting period[90] - The largest shareholder, Aoyang Group Co., Ltd., holds 42.96% of the shares, amounting to 243,082,979 shares, with 160 million shares pledged[90][91] - The company has committed to not transferring more than 25% of its shares during the tenure of its major shareholders, with a long-term commitment to protect minority shareholders[77] Related Party Transactions - The total amount of related party transactions for the company reached 23.54 million yuan, with the largest transaction being the sale of electricity amounting to 2,247.91 million yuan, accounting for 49.61% of similar transactions[66] - The company maintains independence from related parties in terms of business, personnel, finance, assets, and institutions, ensuring that related party transactions do not affect its independence[66] Future Outlook - The company has set a performance guidance of 1.8 billion RMB in revenue for 2014, reflecting a growth target of 20%[105] - The company plans to continue expanding its market presence and investing in new technologies[178] - The financial performance indicates a positive outlook for future growth and profitability[178]